Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.
| NCPE Assessment Process | Complete |
| Rapid review received | 20/09/2016 |
| Rapid review completed | 28/09/2016 |
| Rapid Review outcome | Full pharmacoeconomic assessment recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 10/10/2016 |
| Pre-submission consultation | 11/11/2016 |
| Submission received from applicant | 20/12/2016 |
| Preliminary review sent to applicant | 24/05/2017 |
| NCPE assessment re-commenced | 30/05/2017 |
| Request for further information from applicant (1) | 13/06/2017 |
| NCPE assessment re-commenced | 15/06/2017 |
| Request for further information from applicant (2) | 16/06/2017 |
| NCPE assessment re-commenced | 21/06/2017 |
| Applicant Factual Accuracy Check | 04/07/2017 |
| NCPE assessment completed | 28/07/2017 |
| Full pharmacoeconomic assessment outcome | Reimbursement not recommended |
Following NCPE assessment of the applicant’s submission, cost effectiveness of palbociclib (Ibrance®) for this indication has not been demonstrated, and therefore it is not recommended for reimbursement.
The HSE has approved reimbursement following confidential price negotiations; June 2018